Long-term adjustment of stable asthma treatment with fractional exhaled nitric oxide and sputum eosinophils

European Journal of Inflammation

Volumn 10, Issue 3, 2012, Pages 383-392

  Malerba, Mario ^a   Ragnoli, B ^b   Radaeli, A ^b   Ricciardolo, F L M ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b SPEDALI CIVILI   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

Airway inflammation; Asthma treatment; Exhaled nitric oxide; Sputum eosinophils

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE; BRONCHODILATING AGENT; CORTICOSTEROID; METHACHOLINE; NITRIC OXIDE;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DYSPNEA; EOSINOPHIL; EXPIRED AIR; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; LOW DRUG DOSE; LUNG FUNCTION TEST; MALE; RESPIRATORY TRACT ALLERGY; SCORING SYSTEM; SPIROMETRY; WHEEZING;

EID: 84873455358     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1201000314     Document Type: Article

References (31)

1. Global Strategy for Asthma Management and Prevention (GINA) 2011 (update). Available on www.ginasthma.org
2. Jatakanon A, Sim L, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax 1998; 53:91-95. (Pubitemid 28212132)
3. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev 2004; 84(3):731-65. (Pubitemid 38823765)
4. Ricciardolo FLM, Di Stefano A, Silvestri M, Van Schadewijk, Malerba M, Hiemstra PS, Sterk PJ. Exhale nitric oxide is related to bronchial eosinophilia and airway hyperresponsiveness to bradykinin in allegen-induced asthma exacerbation. Int J Immunopathol Pharmacol 2012; 25(1):175-82.
5. Pavord ID, Wardlaw AJ. The A to E of airway disease. Clin Exp Allergy 2010; 40(1):62-7.
6. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, Chang AB. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012; 67(3):199-208.
7. Montuschi P, Barnes PJ. New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today 2011; 16(23-24):1084-91.
8. Malerba M, Ragnoli B, Radaeli A, Tantucci C. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthma. Chest 2008; 134(4):733-9.
9. Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying "well controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respir Med 2005; 100:616-21 (Pubitemid 43285748)
10. Clausen JL, Coates AL, Quanjer PH. Measurement of lung volumes in humans: review and recommendations from an ATS/ERS workshop. Eur Respir J 1997; 10:1205-6 (Pubitemid 27278234)
11. American Thoracic Society. Guidelines for methacholine and exercise challenge testing. Am J Respir Crit Care Med 1999; 161:309-29
12. ATS/ERS recommendations for standardized procedures for online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005; 171:912-30.
13. Olivieri M, Talamini G, Corradi M, Perbellini L, Mutti A, Tantucci C, Malerba M. Reference values for exhaled nitric oxide (REVENO) study. Respir Res 2006; 7:94-99.
14. Malerba M, Ricciardolo F, Radaeli A, et al. Neutrophilic inflammation and IL-8 levels in induced sputum of α-1- antitrypsin PiMZ subjects. Thorax 2006; 61:129-33. (Pubitemid 43235429)
15. Balbi B, Pignatti P, Corradi M, et al. Bronchoalveolar lavage, sputum and exhaled clinically relevant inflammatory markers: values in healthy adults. Eur Respir J 2007; 30:769-81. (Pubitemid 351194840)
16. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, Wardlaw AJ, Pavord ID. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002; 360:1715-21. (Pubitemid 35447900)
17. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006; 27:483-94. (Pubitemid 43372521)
18. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005; 352:2163-73.
19. Pijnenburg MW, Bakker EM, Hop WC, de Jongste JC. Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial. Am J Respir Crit Care Med 2005; 172:831-6. (Pubitemid 41369065)
20. Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007; 176:231-7. (Pubitemid 47195872)
21. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008; 372:1065-72.
22. de Jongste JC, Carraro S, Hop WC, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. Am J Respir Crit Care Med 2009; 179:93-7.
23. Mahut B, Trinquart L, Le Bourgeois M, et al. Multicentre trial evaluating alveolar NO fraction as a marker of asthma control and severity. Allergy 2010; 65(5):636-44.
24. Powell H, Murphy VE, Taylor DR, Hensley MJ, McCaffery K, Giles W, Clifton VL, Gibson PG. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet 2011; 378:983-90.
25. Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications. Clin Respir J 2009; 3(4):198-206.
26. Dweik RA, Boggs PB, Erzurum SC, et al. American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184(5):602-15.
27. Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clin Exp Allergy 2009; 39(4):478-90.
28. Montuschi P, Currò D, Ragazzoni E, Preziosi P, Ciabattoni G. Anaphylaxis increases 8-isoprostaglandin F2alpha release from guinea-pig lung in vitro. Eur J Pharmacol 1999; 15365(1):59-64. (Pubitemid 29070720)
29. Barreto M, Villa MP, Olita C, Martella S, Ciabattoni G, Montuschi P. 8-Isoprostane in exhaled breath condensate and exercise-induced bronchoconstriction in asthmatic children and adolescents. Chest 2009; 135(1):66-73.
30. Montuschi P, Santonico M, Mondino C, et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest 2010; 137(4):790-6.
31. Montuschi P, Peters-Golden ML. Leukotriene modifiers for asthma treatment. Clin Exp Allergy 2010; 40(12):1732-41.